Azilsartan in Chinese Patients With Mild and Moderate Hypertension
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 304 participants.
Also called NCT02609490
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 304 participants
- Sponsor
- Registry
-
NCT02609490
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT02609490. Randomized; triple masking; primary purpose treatment. Start 2015-09 (actual); primary completion 2017-02 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Azilsartan in Chinese Patients With Mild and Moderate Hypertension
- Condition
- Hypertension
- Intervention (Drug)
- Azilsartan tablets
- Intervention (Drug)
- Azilsartan placebo tablets
- Intervention (Drug)
- Olmesartan medoxomil tablets
- Intervention (Drug)
- olmesartan medoxomil placebo tablets
- Lead sponsor
- Lee's Pharmaceutical Limited
Record details
- Record id
cardio:ct-nct02609490- Content hash
dde671879650494ac230c4aa6933f0b3ae73e45ade19117d612fb5b7104bca23